You can read our Premium News Service in full if you have an Annual Subscription to the OTCToolbox website. You can read Basic News stories free of charge.
28 May 2021
AFT Pharmaceuticals reported sales up by 7% to NZD113 million (USD81.6 million) in the 12 months ended 31 March 2021. The New Zealand company said the tablet version of its Maxigesic combination painkiller was available in 43 countries at the end of the 12-month period, up from 28 a year earlier.
8 April 2021
New Zealand’s AFT Pharmaceuticals has signed a licensing agreement for its Maxigesic combination painkiller with Polish company Mercapharm. The company has also revised its financial guidance following delays and disruptions related to the COVID-19 pandemic.
13 January 2021
Maxwellia has appointed a finance director, Bayer has recruited a chief transformation and talent officer, and AFT Pharmaceuticals has gained expertise in North America.
24 November 2020
New Zealand’s AFT Pharmaceuticals has opened a European office and signed up distribution partners for the oral tablet version of its Maxigesic combination painkiller in Greece, Pakistan and Ecuador.
21 July 2020
Alcon is extending its Pataday OTC range in the US, Karo Pharma and Venture Life have released financial results, while AFT Pharmaceuticals is working with RooLife Group to launch an online health and pharmacy store in China.
19 June 2020
AFT Pharmaceuticals, owner of the Maxigesic combination painkiller, has raised around NZD10 million (USD6.47 million) through issuing new shares. The New Zealand-based company said the move would “increase liquidity and reduce debt”.
25 March 2020
New Zealand’s AFT Pharmaceuticals says it is experiencing strong demand for a number of its products, including Maxigesic and Vitamin C Lipo-Sachets, due to the COVID-19 pandemic.